Reply to the comment of Wilbrink <i>et al</i>. on Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes: The association between remaining β‐cell function and the achievement of the HbA1c target 1 year after initiation
Journal of diabetes investigation